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ABSTRACT
Recent experimental evidence suggests that acute myeloid leukemias may origi-
nate from multiple clones of malignant cells. Nevertheless it is not known how the
observed clones may differ with respect to cell properties such as proliferation and
self-renewal. There are scarcely any data on how these cell properties change due to
chemotherapy and relapse. We propose a new mathematical model to investigate the
impact of cell properties on multi-clonal composition of leukemias. Model results imply
that enhanced self-renewal may be a key mechanism in the clonal selection process.
Simulations suggest that fast proliferating and highly self-renewing cells dominate at
primary diagnosis while relapse following therapy-induced remission is triggered mostly
by highly self-renewing but slowly proliferating cells. Comparison of simulation results
to patient data demonstrates that the proposed model is consistent with clinically ob-
served dynamics based on a clonal selection process.
Keywords: clonal evolution, leukemia, cancer stem cells, mathematical models, selec-
tion process
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1 Introduction
Leukemia is a clonal disease of the hematopoietic system leading to extensive expansion
of malignant cells that are non functional and cause impairment of blood cell formation.
Recent experimental evidence indicates that the malignant cell population might be
composed of multiple clones [1], maintained by cells with stem-like properties [2,3]. A
clone consists of genetically identical stem and non-stem cells. Relapse of the disease
after therapy is a common problem of leukemias [1].
To understand better origins of acute leukemia relapses, a genetic interdependence
between clones at diagnosis and relapse has been investigated using gene sequencing
and other techniques. In most cases of acute lymphoblastic leukemia (ALL) the clones
dominating relapse have already been present at diagnosis but undetectable by routine
methods [4–6]. Due to quiescence, very slow cycling or other intrinsic mechanisms, [5,6]
these clones survive chemotherapy and eventually expand [5, 6]. This implies that
the main mechanism of relapse in ALL is based on a selection of existing clones and
not an acquisition of therapy-specific mutations [5]. Similar mechanisms have been
described for acute myeloid leukemia (AML), where clones at relapse are genetically
closely related to clones at primary diagnosis [1,7] and did not have to acquire additional
mutations during the course of disease [8, 9].
Based on these findings the evolution of malignant neoplasms can be interpreted
as a selection process [10–12] of cells with properties that enable them to survive
treatment and to expand efficiently. Cells with different mutations may have different
growth properties [1]. Chemotherapy significantly alters growth conditions of cells and
therefore, it may have a strong impact on the selection process. If cells dominating at
diagnosis are sensitive to therapy, minor clones with intrinsic resistance [5, 6, 13] may
expand more efficiently once the competing clones are eliminated by the treatment. The
latter could explain manifestation of different cell clones at diagnosis and at relapse
without a need for additional mutations in between.
The mechanism of the underlying selection process and its impacts on the disease
dynamics and on the response of cancer cells to chemotherapy are not understood.
Gene sequencing studies allow to decipher the genetic relation between different clones,
nevertheless the impact of many detected mutations on cell behaviour remains un-
clear [1] and often passenger mutations cannot be distinguished from relevant genetic
changes [4]. Many authors, e.g. [14, 15], have provided evidence for the heterogeneity
of LSCs attempting to identify the LSC characteristics, for review see [16]. This het-
erogeneity is further supported by the results of gene sequencing studies [1,17,18]. The
multifactorial nature of the underlying processes severely limits the intuitive interpre-
tation of experimental data. Mathematical modelling is a powerful technique to close
this gap and to provide quantitative insights into cell kinetics, fate determination and
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development of cell populations. It allows a systematic study of processes not yet ac-
cessible by experimental procedures. Mathematical models have been widely applied
to analyze the regulatory mechanisms controlling the hematopoietic system and its
diseases: for review see [19–22] and references therein.
The aim of this work is to investigate the impact of cell growth properties on the
clonal selection process in acute leukemias before and after treatment. We introduce
mathematical models of dynamics of leukemia, which are extended versions of the
models proposed earlier by our group [23–25]. The novel ingredients of the models
in this work are: (i) heterogeneity and multiclonal structure of LSCs, (ii) different
plausible feedback mechanisms, and (iii) effects of chemotherapy.
Since the mechanism of interaction between healthy and leukemic cell lines is not
well identified, we propose two models (see Fig.1). In the first one, we assume that
leukemic cells depend on hematopoietic growth factors and interact with hematopoietic
cells via competition for these factors. The second model is based on the assumption
that autonomous leukemic clones compete with hematopoietic cells for niches in bone
marrow, which leads to an increased cell death due to over-crowding. The latter is
supported by experimental findings showing signal-independent activation of important
cell functions [26–28] and by an increased cell degradation observed in leukemic patients
[29–31]. Such interactions have not been considered in previous models.
The models proposed in this paper do not account for new mutations. Motivated by
the experimental findings described above [5,6,8,9], we rather aim to understand which
aspects of the dynamics of leukemias can be explained by a selection process alone. It is
interesting, since expansion of a clone at relapse that could not be detected at diagnosis
due to limited sensitivity of methods can be misinterpreted as occurrence of mutations
[5]. This scenario seems to be relevant in case of acute leukemias with a short duration
treatment administration. Many acute leukemias are genetically relatively stable in
comparison to other cancers [32, 33]. For this reason on average many replications
are necessary to acquire a new mutation. Consequently, it is less probable that cells
acquire mutations during short treatment and, therefore, intrinsic resistance to therapy
may be important, as suggested by available evidence [5]. The latter does not hold
true for long-term drug administration, such as imatinib treatment in case of chronic
leukemias. For this reason, our work focuses on the acute leukemias. For completeness
of this work and to check how mutations might influence the model dynamics as it
concerns results presented in this paper, we have developed a version of the model
with mutations. The simulations of the model confirm our conclusions for the model
with mutations. The model and simulations are presented in Appendix.
Using mathematical models, we aim to identify which cell properties are compat-
ible with intrinsic resistance to therapy and efficient expansion after treatment, and
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to compare them with the cell properties selected for before treatment. We perform
computer simulations describing evolution of multi-clonal population of leukemic cells
during the disease development and the contribution of different clones to the entire
cancer cell population at different time points. The heterogeneity of the system is
given by a certain number of leukemic clones already present at the beginning of our
observation. The models provide information on the influence of cell properties on the
growth dynamics of the different clones in presence or in absence of chemotherapy. This
allows to understand how the cell properties selected for before treatment differ from
those selected for during and after treatment and how treatment could be optimised
to reduce relapses. Finally, we compare qualitatively model simulations to patients’
data from clinical routine to show that the proposed models are consistent with clin-
ical observations concerning the response to therapy and the time intervals between
relapses of the disease. Details of mathematical formulation and parametrisation of
the proposed models are presented in Appendix.
2 Methods
2.1 Mathematical Models
2.1.1 Model assumptions
The models used in this study are based on the models of healthy hematopoiesis pro-
posed and analysed in [23, 34–36] and extended to account for evolution of a single
leukemic clone in [25].
Based on the classical understanding of hematopoiesis [37], we assume that the sys-
tem consists of an ordered sequence of different maturation states, so called compart-
ments. To describe time evolution of cell populations, we apply ordinary differential
equations. The enormous amount of cells forming the hematopoietic system justifies
this approach [37,38]. Evolution of small cell population in the post-therapy period is
modeled by cutting off the initial data which are below a minimal threshold, as it was,
for example, proposed in [39].
We model time dynamics of one healthy cell lineage and an arbitrary number of
leukemic clones. In the description of cell differentiation within each cell line, we choose
a two-compartment version of the multi-compartment system established in [23]. The
model focuses on the maintenance of primitive cells and differentiation from undiffer-
entiated, proliferating cells to differentiated, post-mitotic cells. In the case of healthy
hematopoiesis, the proliferating cells are hematopoietic stem cells (HSC), hematopoi-
etic progenitor cells (HPC) and precursor cells, the post-mitotic cells are mature cells,
e.g., white cells. The two-compartment architecture is based on a simplified descrip-
4
tion of the multi-stages differentiation process. Nevertheless as shown in [24], [35],
and [36] models consisting of two compartments capture the desired dynamics of the
multi-compartmental cell population. This allows to reduce the complexity of the dif-
ferentiation process to focus on mechanisms and effects of competition between different
cell lines.
Each proliferating cell type is characterised by the following cell properties:
• Proliferation rate, describing how often a cell divides per unit of time.
• Fraction of self-renewal, describing the fraction of daughter cells returning to the
compartment occupied by the mother cells that gave rise to them. Based on
our earlier work and on compatibility with clinical data [23], we assume that the
fraction of self-renewal of hematopoietic cells is regulated by feedback-signalling.
• Death rate, describing what fraction of cells dies per unit of time. For simplic-
ity, we assume that under healthy conditions proliferating cells do not die and
post-mitotic mature blood cells die at a constant rate. We assume the same for
leukemic cells in Model 1, while in Model 2 (see below), we consider, additionally,
cell density- dependent death rates for all bone marrow cell types if the mar-
row space is overcrowded. The considered marrow cell types include immature
hematopoietic cells and mitotic and post-mitotic leukemic cells. Overcrowding is
defined when marrow cell counts exceed the steady state marrow cell count for 2
to 3 times. In this case the death rate of post-mitotic leukemic cells consists of
their intrinsic death rate and the death triggered by spatial competition.
Production of healthy blood cells is regulated by a negative feedback [40–42], me-
diated by cytokines, such as G-CSF or EPO [37,42,43]. If there is a shortage of blood
cells of a certain type, the concentration of signalling molecules increases and stimu-
lates expansion of precursor cells. This effect is modeled using a negative feedback loop
as proposed in [23]. Analysis and simulation of the model of healthy hematopoiesis,
validated based on the clinical observations after stem cell transplantations [23,44,45],
indicate that the regulation of the self-renewal is a more efficient mechanism than the
regulation of the proliferation rates. Similar conclusions have been drawn using the
models of multistage cell lineages applied to regeneration and maintenance of the mouse
olfactory epithelium [46,47]. Therefore, in the remainder of this paper we assume that
the regulatory mechanism is based on the feedback inhibition of self-renewal depending
on the level of mature cells.
2.1.2 Model of the healthy cell line
We denote by pc the proliferation rate of mitotic hematopoietic cells and by ac the
corresponding fraction of self-renewal. The death rate of mature blood cells is denoted
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by dc2. We denote the concentration of healthy cell types at time t by c1(t), c2(t), corre-
sponding to mitotic and mature cells, respectively. The flux to mitosis at time t equals
pc(t)c1(t). During mitosis, a mother cell is replaced by two daughter cells. The outflux
from mitosis at time t equals 2pc(t)c1(t), of which the fraction 2a
c(t)pc(t)c1(t) stays in
compartment 1 (process referred to as self-renewal). The fraction 2
(
1−ac1(t)
)
pc(t)c1(t)
moves to compartment 2 (process referred to as differentiation).
We denote the value of the feedback signal at time t by s(t), which takes values
between zero and one. Self-renewal of a certain cell type at time t is assumed to be given
as a maximal possible self-renewal of this cell type multiplied by s(t). Following [23,25],
we chose s(t) = 11+kcc2(t) , which can be derived from cytokine kinetics [23]. The
constant kc depends on the rate of extra-hematopoietic cytokine degradation by liver
or kidney and on the rate of cytokine degradation by hematopoietic cells. The latter
depends on the densities of cytokine receptors on hematopoietic cells [45].
We obtain the following system of ordinary differential equations, where acmax cor-
responds to the maximal possible self-renewal of hematopoietic stem cells.
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t) (1)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t) (2)
s(t) =
1
1 + kcc2(t)
(3)
The two different models proposed in this manuscript differ with respect to the interac-
tion of leukemic and hematopoietic cells. We consider two cases. In Model 1 leukemic
cells depend fully on hematopoietic cytokines whereas in Model 2 they are totally in-
dependent of environmental signalling. In this sense Model 1 and Model 2 can be
understood as the two opposite extremes of a continuum. In reality both mechanisms,
competition for environmental signals and direct inhibition or death of hematopoietic
cells, may contribute to impaired hematopoietic function [48]. A schematic represen-
tation of the models is given in Fig 1.
2.1.3 Model 1
We assume that leukemic cells depend on the same feedback signal as their healthy
counterparts and that the post-mitotic leukemic cells (blasts) decrease the supply of
the factor. It describes a competition between healthy and leukemic cells for survival
signals, which results in down-regulation of self-renewal. A schematic representation
of the model is given in Fig 1.
To write the corresponding equations, we denote the number of leukemic clones by
n. As for the hematopoietic cells we consider mitotic and post-mitotic cell compart-
6
ments for each leukemic clone. Let pl
i
denote the proliferation rate of mitotic cells
in leukemic clone i and al
i
max the corresponding maximal fraction of self-renewal. By
dl
i
2 > 0 we denote the clearance rate of post-mitotic cells of clone i. Denote by l
i
1(t)
the level of mitotic cells of clone i and by li2(t) the level of post-mitotic cells at time t.
These assumptions result in the following system of ordinary differential equations:
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t) (4)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t) (5)
d
dt
l11(t) =
(
2al
1
maxs(t)− 1
)
pl
1
l11(t) (6)
d
dt
l12(t) = 2
(
1− al1maxs(t)
)
pl
1
l11(t)− dl
1
2 l
1
2(t) (7)
...
...
... (8)
d
dt
ln1 (t) =
(
2al
n
maxs(t)− 1
)
pl
n
ln1 (t) (9)
d
dt
ln2 (t) = 2
(
1− alnmaxs(t)
)
pl
n
ln1 (t)− dl
n
2 l
n
2 (t) (10)
s(t) =
1
1 + kcc2(t) + kl
∑n
i=1 l
i
2(t)
. (11)
The expression for s(t) is a special case of s˜(t) = 1/
(
1+kcc2(t)+
∑n
i=1 k
l
il
i
2(t)
)
, where
we assume that kli = k
l for all i. This simplification corresponds to the observation
that the density of cytokine receptors is similar on cells of all leukemic clones. For the
major cytokine of the myeloid line, G-CSF [41], this is is true for many patients [49].
Since there is evidence that in some patients receptor densities may differ between
different leukemic clones [49], we have repeated all simulations with a randomly chosen
kli value for each clone, ranging from 30% of k
c to 100% of kc. This heterogeneity had
no significant impact on the model results. Since in many cases the receptor density on
leukemic cells is of the same order of magnitude as that on hematopoietic cells [49,50],
we assume also kl = kc for the simulation of patient examples.
2.1.4 Model 2
There is evidence that in some leukemias malignant cells show constitutive activation
of certain signalling cascades and thus may become independent of external signals
[26–28]. We consider this scenario in Model 2. In contrast to Model 1, we assume that
leukemic cells are independent of hematopoietic cytokines, whereas the hematopoietic
cell types depend on the nonlinear feedback described above. Interaction between the
healthy and cancer cell lines is modeled through a competition for space resulting in
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an increased cellular degradation, for example due to overcrowded bone marrow space.
This is consistent with the observation of an increase of markers for cell death such
as LDH [29–31]. Several mechanisms underlying this spatial competition have been
proposed: (i) physical stress due to overcrowding leads to extinction of cells (e.g., [51];
recently challenged by [52]), (ii) competition for a limited niche surface expressing
certain receptors (contact molecules) necessary for survival of the cells [53, 54] and
apoptosis if no contacts to these molecules can be established [55].
We model the space competition by introducing a death rate that increases with
the number of cells in bone marrow and acts on all cell types residing in bone marrow,
i.e., mitotic and post-mitotic leukemic cells as well as mitotic hematopoietic cells. For
simplicity we assume in Model 2 that all leukemic cells stay in bone marrow, since the
number of leukemic cells exiting bone marrow is highly variable among individuals and
only partially dependent on the leukemia subtype [56–58] and since it is not well under-
stood which mechanisms are responsible for marrow egress and high inter-individual
variability. The presented results are robust with respect to this assumption: We re-
peated all simulations for the cases that 10%, 50% or 90% of the most mature leukemic
blasts exit bone marrow. This has impact on the time dynamics of marrow blast count
but does not influence the cell properties that are selected for.
Let d(x) be an increasing function with limx→∞ d(x) =∞. This function describes
the death rates of bone marrow cells in dependence of bone marrow cell counts x. We
assume that under healthy conditions there exists no cell death due to overcrowding.
Enhanced cell death can be observed only if total bone marrow cellularity increases
beyond the threshold level. This assumption is in line with bone marrow histology [59].
Therefore, we assume that d(x) = 0 for x ≤ c¯1, where c¯1 is the steady state count of
mitotic healthy cells.
Assuming that the hematopoietic cell lineage is regulated as described above, we
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obtain the following system of differential equations:
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− d(x(t))c1(t) (12)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t) (13)
s(t) =
1
1 + kcc2(t)
(14)
d
dt
l˜11(t) =
(
2al˜
1 − 1)pl˜1 l˜11(t)− d(x(t))l˜11(t) (15)
d
dt
l˜12(t) = 2
(
1− al˜1)pl˜1 l˜11(t)− dl˜12 l˜12(t)− d(x(t))l˜12(t) (16)
...
...
... (17)
d
dt
l˜n1 (t) =
(
2al˜
n − 1)pl˜n l˜n1 (t)− d(x(t))l˜n1 (t) (18)
d
dt
l˜n2 (t) = 2
(
1− al˜n)pl˜n l˜n1 (t)− dl˜n2 l˜n2 (t)− d(x(t))l˜n2 (t) (19)
x(t) = c1(t) +
n∑
i=1
l˜i1(t) +
n∑
i=1
l˜i2(t). (20)
Here l˜i1 denotes the mitotic cells of clone i, a
l˜i their fraction of self-renewal and pl˜
i
their
proliferation rate. The level of post-mitotic cells of clone i is denoted as l˜i2. In absence
of marrow overcrowding these cells die at rate dl˜
i
2 .
2.1.5 Chemotherapy
We focus on classical cytotoxic therapy acting on fast dividing cells, which is introduced
to the models by adding a death rate proportional to the proliferation rate. The
assumption is motivated by the fact that many of the classical therapeutic agents used
for treatment of leukemias act on cells in the phase of division or DNA replication, [60].
Therefore, the rate of induced cell death is proportional to the number of cycling cells.
We assume that the linear factor, denoted by kchemo, is identical for all mitotic cells.
Under chemotherapy, the equation for mitotic hematopoietic cells in Model 1 takes the
form
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− kchemo · pc · c1(t). (21)
Similarly, we obtain for mitotic cells of leukemic clone i
d
dt
li1(t) =
(
2al
i
maxs(t)− 1
)
pl
i
li1(t)− kchemo · pl
i · li1(t). (22)
Chemotherapy in Model 2 is introduced analogously.
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2.2 Simulations
We perform numerical simulations of the models to investigate which leukemic cell
properties lead to survival advantage during evolution of leukemogenesis and recur-
rence under chemotherapy. As explained before, the models do not account for ad-
ditional mutations taking place during the therapy. Instead, we investigate evolution
of a certain number of leukemic clones present at a starting time point. We assume
that in healthy individuals the hematopoietic cells are in a dynamic equilibrium, i.e.
production of each cell type equals its clearance. Initial conditions for the computer
simulations are equilibrium cell counts in the hematopoietic cell lineage and a small cell
number for different leukemic clones. We assume that the initial number of leukemic
clones in each patient is 50. This number is arbitrarily chosen. All presented simu-
lations were repeated for different numbers of leukemic clones (between 3 and 100),
what led to comparable results (see Supplemental Figures 1 and 2). We assume that
primary diagnosis and diagnosis of relapse occur, when healthy blood cell counts are
decreased by 50% of their steady state value. We perform simulations for 50 patients,
i.e. 50 different sets of initial data and model parameters, with 50 leukemic clones
per patient. The growth properties of the leukemic clones are chosen randomly within
certain ranges. The choice of model parameters is described in the Appendix. The
simulations follow the following algorithm:
(i) We start from healthy equilibrium in the hematopoietic lineage and one mitotic
cell per kg of body weight for each leukemic clone and run simulations until the
number of healthy mature blood cells decreases by 50%. We investigate proper-
ties of the clones with the highest contribution to the total leukemic cell mass.
The clones under consideration are those which together constitute 80% of the
total leukemic cell mass. In the following we denote these clones as ’significantly
contributing clones’. This procedure is taken to reflect the sensitivity of the de-
tection methods. In more than 90% of the patients 2 to 4 clones sum up to more
than 95% of the total leukemic cell mass. Taking a threshold between 80% and
95% to define ’significantly contributing clones’ has little influence on the result.
Furthermore, more than 97% of the clones that are considered as insignificant by
this method consist of less than 1% of the leukemic cell mass. This number is in
agreement with the detection efficiency reported in literature [61].
(ii) Next, we simulate chemotherapy. For simplification, we consider seven applica-
tions of cytotoxic drugs (one per day during seven following days, corresponding to
standard inductions). Simulations show that the number of drug applications has
no influence on the presented qualitative results. As proposed in literature [39],
we assume that a cell population has become extinct if it consists of less than one
10
cell. Initial conditions for the post-therapy period are obtained from cell counts
after therapy where counts of extinct populations are set to zero. We continue
simulations until mature blood cell counts decrease by 50% and then assess the
cell properties of the clones contributing to relapse.
Calibration of the hematopoietic part of the model to clinical data and parameters
for simulation of two patient examples can be found in Appendix. Since in clinical
routine only few key mutations are monitored, we choose patient examples with differ-
ent key mutations detected at diagnosis and at relapses. Such data is relatively rare,
therefore we focus on two patients. Simulations are performed using standard ODE-
solvers from the Matlab-software package (Version 7.8, The MathWorks, Inc, Natic,
MA) which are based on Runge-Kutta schemes.
3 Results
3.1 Clonality at diagnosis
We solve the models numerically to obtain insight into the contribution of different
leukemic clones to the total leukemic cell mass. Simulations indicate that at the di-
agnosis rarely more than 3-4 clones significantly contribute to the total leukemic cell
mass. In most cases more than 40-50% of the total leukemic cell mass originates from
a single leukemic clone. This finding is identical for both considered models.
3.2 Properties of clones at diagnosis
Simulations indicate that the clones significantly contributing to the leukemic cell mass
have high proliferation rates and high self-renewal potential (high fraction of symmetric
self-renewing divisions). Such configuration of parameters leads to an efficient cell
expansion. The properties of clones contributing significantly to leukemic cell mass at
diagnosis are depicted in Figure 2. This finding is identical for both considered models.
3.3 Clonality at relapse
The clonality at relapse is comparable to the clonality at diagnosis. Rarely more than
three clones significantly contribute to the total leukemic cell mass. This finding is the
same for both considered models.
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3.4 Properties of clones at relapse
The properties of the leukemic clones responsible for relapse depend on the efficiency
of chemotherapy. We run computer simulations for varied efficiency of chemotherapy,
namely different death rates imposed on mitotic cell compartments. In the case of inef-
ficient chemotherapy, i.e. killing rates of mitotic cells being relatively small, the clones
present at diagnosis are also responsible for relapse. These clones have high prolifera-
tion rates and high self-renewal potential. In the case of more efficient chemotherapy,
i.e. killing rates of mitotic cells being higher, the clones responsible for primary pre-
sentation differ from the clones responsible for relapse. Compared to the clones leading
to primary presentation, the clones responsible for relapse have low proliferation rates
but high self-renewal potential. The properties of clones contributing significantly to
leukemic cell mass at diagnosis and at relapse are depicted in Figure 3. Both models
lead to similar results.
The result that slow cycling is an important selective mechanism is compatible with
the finding that cells in minimal residual disease samples are highly quiescent [6]. It is
further supported by the fact that addition of anthracyclines, which act independent
of cell cycle [62], leads to improved outcome of relapse therapies in ALL [63].
3.5 Treatment of relapse
If the same treatment strategy as in case of primary treatment is applied to a relapsed
patient, remission time is significantly shorter (Fig. 4). Second relapse is mostly
triggered by the same clones as primary relapse. With repeated chemotherapy, clonal
composition changes in favor of the clones with minimal proliferation (Clone 5 in Fig.
4). This finding is in agreement with data from clinical practice in ALL suggesting that
the clones selected for at relapse possess inherently reduced sensitivity to treatment [5]
and may be also responsible for second relapse [5]. The dynamics of leukemic cells in
our model are in good agreement with data from clinical practice: Chemotherapy is
able to reduce leukemic cell load after relapses [4], nevertheless this reduction does not
lead to durable remission [63]. This reflects the worse prognosis of relapsed patients
[13, 63, 64]. The increasing fraction of cells with reduced drug sensitivity predicted by
the simulations explains the experimental finding that cells present at relapse are more
resistant to chemotherapy than cells present at initial diagnosis [13, 64]. It also shows
that repetition of the same induction therapy leads to worse results in relapse compared
to primary manifestation [63]. The selection of slowly cycling cells predicted by our
model seems to be an important mechanism in AML. It it was demonstrated that
induction of cell cycling enhances chemo-sensitivity of leukemic cells [65] and improves
patient outcome after therapy [66]. Our model suggests that repeated chemotherapy
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can lead to the selection of clones that are not competitive in natural environment, i.e.
that can be outcompeted by clones sensitive to chemotherapy after cessation of the
treatment.
3.6 Short term expansion efficiency does not correlate
with long term self-maintenance
If leukemic cell behaviour depends on hematopoietic cytokines (Model 1), the current
signalling environment influences expansion of leukemic clones. In this scenario it
is possible that fast proliferating cells with low self-renewal potential dominate the
leukemic cell mass during an initial phase. If, with increasing leukemic cell mass,
self-renewal becomes down-regulated, e.g. due to occupation of bone marrow niche,
eventually the cell clone with the highest affinity to self-renewal survives, although its
proliferation might be slow. An example of time evolution during an early phase is
depicted in Fig. 5.
3.7 Late relapses can originate from clones that were al-
ready present at diagnosis
Simulations of Model 1 indicate that late relapses, e.g., relapses after more that 3 years,
can originate from clones that were already present at diagnosis but did not significantly
contribute to the leukemic cell mass at that time. These relapses are triggered by
very slow proliferating cells which survive chemotherapy and then slowly grow. At
primary diagnosis fast proliferating clones dominate. The slowly proliferating clones
are then selected by chemotherapy. This finding is able to explain relapses without
additional mutations occurring after primary diagnosis. Thus, temporary risk factor
exposure (e.g., chemicals or radiation) can be responsible also for very late relapses
and presentations.
3.8 Comparison of simulations to patient data
To check if the proposed modelling framework is consistent with the observed dynamics
of leukemia, we calibrate the model to data of two patients with multiple relapses. The
selected two patients showed different AML-typical mutations. Properties of leukemic
cells and their impairment due to chemotherapy cannot be measured directly and the
effects of specific mutations on cell dynamics are not well understood. The available
data include time periods between induction/consolidation chemotherapy and relapse
as well as the percentages of leukemic blasts in the bone marrow at diagnosis, follow-
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ups and relapse. In addition emergence and subsequent elimination of leukemia driving
mutations (FLT3, MLL-PTD) in the bone marrow cells were precisely monitored using
molecular biology methods [67–69]. We verify if, and under which assumptions con-
cerning the cell behaviour, the proposed model is compatible with clinical observations.
This can serve as a qualitative ’proof of principle’ and leads to hypotheses concerning
changes in cell properties induced by the respective mutations. We assume that each
mutation is associated with one leukemic cell clone. We interpret differences at diag-
nosis and at relapse as the result of a clonal selection process due to chemotherapy and
cell properties. For this study we apply Model 2, since simulations over a large range
of parameters showed that remissions shorter than 150 days are only compatible with
Model 2.
Simulations of the evolution of leukemic clones in the two patients are depicted
in Figures 6 and 7. The results show that bone marrow blast fraction can be well
described by the model. In Patient 1 FLT3-ITD mutation of a length of 39 bp is
detected at diagnosis. This mutation becomes extinct and the relapse is triggered by
two different FLT3-ITD mutations (42 bp and 63 bp). This behaviour is reproduced
in the model simulation. At diagnosis leukemic cell mass is mainly derived from one
clone while at relapse two different clones contribute to leukemic cell mass.
In Patient 2 FLT3-ITD mutation and MLL-PTD-mutation were both detected at
diagnosis. The MLL-PTD mutation practically did not contribute to relapse. The
model reflects this scenario. At diagnosis two different clones contribute to leukemic
cell mass, one of which becomes extinct and is not detected at the relapse. In this
patient the clone responsible for relapse behaves similarly to the HSC lineage. Thus,
classical cytotoxic treatment would not lead to its eradication. This is an indication for
application of new anti-leukemic drugs, if feasible, or for bone marrow transplantation.
4 Discussion
We have examined the impact of cell properties on clonal evolution in acute leukemias
during the course of disease. We have considered two different mathematical mod-
els, representing different modes of interactions between normal hematopoietic and
leukemic cells. In Model 1 leukemic cells depend on hematopoietic cytokines, niches
or other environmental factors. In Model 2 the leukemic cells are independent of these
aforementioned determinants and the only interaction between benign and malignant
cells is due to a competition for bone marrow space.
Model simulations suggest that clones with a high proliferation rate and a high
self-renewal are favoured at primary diagnosis. The results indicate that the number
of clones significantly contributing to the leukemic cell mass is relatively small, even
14
if a large number of clones with different leukemia driving mutations might coexist in
the bone marrow. For example, in our simulations it was reduced from 50 to 2-5. This
result is in agreement with data from recent gene sequencing studies and allows to
explain these data. In these studies [1,15] at most 4 contributing clones were detected
in case of AML and at most 10 in case of ALL. In many patients this number was even
smaller. Our study implies that clonal selection due to different growth characteristics
is an efficient mechanism to reduce the number of clones contributing to leukemic cell
burden. Clones not contributing to primary disease manifestations might rest in a
slowly proliferating or quiescent state and expand at relapse. Chemotherapy exerts a
strong selective pressure on leukemic clones and thus has a considerable impact on the
clonal composition during relapse.
In the case of insufficient chemotherapy, the relapse can be triggered by the same
clones as the primary disease. In the case of more intensive therapy regimens, relapses
are mostly triggered by different clones than primary disease. This has also been
concluded from experimental studies [1]. Our models suggest that chemotherapy selects
for slowly proliferating clones with high self-renewal property. Depending on efficiency
of the therapy, it is also possible that clones with high proliferation and high self-
renewal potential are responsible for relapse.
In the present study we have focused on classical cytotoxic chemotherapy, mostly
acting on mitotic cells. This explains selection of slowly proliferating clones, among
which those with high self-renewal potential have a competitive advantage, as shown
in earlier studies [23–25]. High proliferation rates constitute a disadvantageous factor
under cytotoxic treatment, since fast proliferating cells are responsive to even mod-
erately intensive therapy regimens. Relapses due to such clones are only possible if
LSCs at the same time have a high self-renewal potential, which is an advantageous
factor for expansion and survival. Otherwise they would be out-competed by slowly
proliferating cells with high self-renewal. Fast proliferating cells with low self-renewal
have never been observed at relapse in our simulations. Their emergence at relapse
could only be explained by additional mutations acquired after initial treatment. The
selection of slowly proliferating cells may explain emergence of resistance in relapses.
In such case, applying an identical therapeutic regimen to primary presentation and
relapse has limited effects in the absence of new mutations.
The principle of clonal competition in leukemia evolution and the fact that resis-
tant subclones might be responsible for relapse have been discussed for a long time [5].
Using mathematical modelling, we have provided for the first time evidence that self-
renewal potential is a major force behind this mechanism and that cells responsible for
a relapse show high self-renewal in nearly all cases. This finding is new and cannot be
concluded from biological data so far.
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In the Appendix we study a model that includes occurrence of new mutations in
addition to the selection process. In this scenario the number of clones detectable
at diagnosis and at relapse and their respective properties are practically identical to
the scenario without mutations. This finding underlines that clonal selection has an
important impact on the evolution of leukemic cell properties.
The exact nature of interaction between leukemic and hematopoietic cells is not
well understood. Moreover, it is well known that leukemias show high inter-individual
heterogeneity concerning symptoms and survival [70]. Therefore, it is possible that
different mechanisms may be relevant in different cases. Simulation results suggest
that the evolving cell properties are robust with respect to the assumptions on the
exact mode of interaction between hematopoietic and leukemic cells and are similar
in different scenarios and different patients. Common features of both models are:
(i) Relapses can be explained by cells that were already present at diagnosis. (ii)
Before therapy clonal evolution selects for cells with high proliferation rate and high
self-renewal. (iii) Cytotoxic treatment selects for cells with slow proliferation and high
self-renewal. Thus, it is possible to draw conclusions on leukemic cell properties, even
if their interaction with the healthy hematopoiesis is not known in detail.
Nevertheless the two proposed models exhibit some different dynamical properties,
namely: (i) Complete remissions lasting shorter than 150 days are only possible in
Model 2. (ii) In Model 2 it is possible that leukemic and non-leukemic cells coexist at
ratios compatible with sufficient hematopoiesis for long times. (iii) In Model 1 clones
can temporarily expand and then be outcompeted. In Model 2 the clone with fastest
expansion is dominant for all times until treatment. (iv) In Model 2 leukemic cell load
can be reduced to a new steady state under chronic application of cytostatic drugs. In
Model 1 expansion of leukemic cells can be reduced in speed but eventually healthy
hematopoiesis will be outcompeted. This may have application in treatment of fast
relapsing patients, since fast relapse can only be explained by Model 2.
Up to now it cannot be decided which model is more realistic. For each of the models
there exist supportive findings. Model 1 is supported by observations on expression
of growth factor receptors by leukemic cells similar to those by hematopoietic cells
[49, 50], expansion of leukemic cells in presence of cytokines in some patients [71]
and dependence of leukemic cell self-renewal and proliferation on chemokines needed
for hematopoietic cell maintenance [72]. The facts supporting Model 2 are enhanced
cell death in marrow samples [73] and increased markers for cell death/cell lysis in
serum [29,74], independence of leukemic cells from important environmental signalling
cues in presence of some mutations [26] and necessity of physical contacts to marrow
stromal cells needed for cell survival [53–55]).
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Our models support the hypothesis that processes of clonal selection are important
mechanisms of leukemia relapse, which can be responsible for expansion of different
cell clones without a need for new mutations. A testable prediction of our models is
that more sensitive methods should reveal larger numbers of different clones that exist
but do not significantly contribute to the leukemic cell mass. Another prediction is
that cells present at relapse show mutations responsible for high self-renewal.
Calibration of the models to patient data shows that the proposed framework is
compatible with the observed clinical course in the considered two data sets. The pre-
dicted selection of slowly proliferating cells with high self-renewal ability is consistent
with clinical observations. Our results may have relevance for personalised medicine.
Deep sequencing techniques might provide information on the genetic interdependence
of the clones present at diagnosis and relapse [1]. Our model suggests that insufficient
therapy may lead to presence of the same clones at diagnosis and relapse. If the clones
present at diagnosis and relapse are not identical but related, i.e., they share common
somatic mutations [1], relapse may be due to a selection process. In this case it is
probable that the clones present at relapse show a slow proliferation and a high self-
renewal. One possible implication might be the application of cell-cycle independent
drugs, such as those used in targeted therapies.
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5 Appendix
5.1 Calibration of the hematopoietic cell lineage
In absence of leukemic clones, both considered models reduce to the same model of the
hematopoietic system. In steady state this model has the following form
0 = (2acs¯− 1)pcc¯1 (23)
0 = 2(1− acs¯)pcc¯1 − dc2c¯2 (24)
s¯ =
1
1 + kcc¯2
(25)
Assume we know c¯1 and c¯2. It holds
c¯2
c¯1
=
pc
dc2
(26)
c¯2 =
2ac − 1
kc
(27)
Knowing ac, we can calculate kc = (2ac − 1)/c¯2, such that the steady state population
size c¯2 is satisfied. We calibrate the model to the data on production of neutrophil
granulocytes, which constitute the majority of mature white blood cells (50%− 70%).
Lymphocytopoiesis is a complicated process involving lymphatic organs and not only
the bone marrow [75]. Therefore, we restrict ourselves to the myeloid line. It holds
for the steady state count of neutrophils [76], c¯2 ∈ (3− 5.8) · 109/l. We interpret c¯1 as
the total amount of mitotic neutrophil precursors in bone marrow. Based on the data
from [59] we assume that about 20% of bone marrow cells are mitotic precursors of
neutrophils (the interindividual variations are considerable). The total bone marrow
cellularity is about 1010 cells per kg of body weight [77]. Therefore, we take
c¯1 ≈ 2 · 109/kg. (28)
Assuming an average blood volume of 6 liters and an average body weight of 70 kg, we
calculate a mature neutrophil count of
c¯2 ≈ 4 · 108/kg. (29)
Neutrophils have half-life in blood stream, T1/2, of about 7 hours [78]. From this we
calculate
dc2 =
ln(2)
T1/2
≈ 2.3/days. (30)
We obtain
pc =
c¯2
c¯1
dc2 ≈ 0.45/day, (31)
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i.e., about once per 1.5 days. We know from bone marrow transplantation [79] that
patients need about 15 days to reconstitute to 5 · 108 neutrophils per liter of blood
(4 · 107 per kg ) after infusion of 5 · 106 immature cells per kg of body weight. For
ac ≈ 0.87 (32)
this constraint is met.
5.2 Model parameters
For the hematopoietic branch we chose parameters obtained from the calibration in
the Section above. For simplicity we assume kc = kl for the feedback mechanism in
Model 1. We set the clearance rate of blasts (in absence of effects of overcrowding)
to dl
i
2 = 0.1. This is based on the apoptotic indices (fraction of dying cells) reported
in literature which are ≈ 0.19 ± 0.16 (19% ± 16%) [80, 81]. Choosing blast clearance
between 0.1 and 0.5 changes the speed of leukemic cell accumulation but, as revealed
by additional simulations, not the cell properties that are selected.
We chose d(x) = dconst ·max{0, x−xmax}. In histological images of healthy adult
bone marrow a large part of the bone marrow cavity consists of fat and connective
tissue and is free of hematopoietic cells. To reflect this fact, we set xmax ≈ 2c¯1, where
c¯1 is the steady state count of mitotic healthy cells. In the simulations, dconst was set
to 10−10. This choice implies that if bone marrow cell counts are three times higher
than in the steady state, the additional death rate due to overcrowding is of the order
of magnitude of mature cell clearance. The results remain unchanged qualitatively,
even if values of dconst vary within different orders of magnitude.
We apply chemotherapy on seven following days for 2 hours. Different treatment
intervals lead to comparable results. In the depicted simulations kchemo has been set
to values between 20 and 30 for less efficient therapy and to values between 40 and
60 for efficient chemotherapy. For different choices similar results are obtained. The
higher kchemo, the stronger the selection for high self-renewal and slow proliferation and
the lower the probability of relapse. The lower kchemo, the higher the probability that
clones contributing to primary presentation are among clones contributing to relapse.
For kchemo between 40 and 45, the obtained results are similar to the results obtained
in experiments [1]. The parameters of the leukemic clones are chosen randomly from
uniform distributions, assuming that cells divide at most twice per day and that self-
renewal is between zero and one.
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5.3 Calibration to patient examples
Both patients were treated within clinical trials at the University Hospital of Heidel-
berg after obtaining their written consent. Details on the patients’ characteristics and
therapeutic regimens can be found in Supplemental Table 1. Model parameters can be
found in Supplemental Tables 2 and 3. For both patients the presence of specific key
mutations was assessed in clinical routine. We chose cases where mutations get lost due
to treatment and new mutation are detected at relapse. We interpret this as the result
of clonal evolution. Since the two patients harbour different mutations, their leukemic
cells can have different properties. Chemotherapy is modeled by increasing death rates
for mitotic cell types during the duration of each cycle. For simplicity, we did not
model kinetics of single chemotherapeutic agents. Instead, the therapy-induced death
rates are assumed to remain constant from the first to the last day of each treatment
cycle. In pharmacology, the exposition to a drug is measured using the ’area under
the curve’ (AUC). This is the integral of concentration (or drug effect) over time [82].
The AUC in our case is kchemo ·∆t, where ∆t is the period of drug action. The AUC
over one day of therapy is similar for the single patient examples and the simulations
in Figure 3. Only myeloablative treatment before transplantation has a higher AUC.
The presented results are based on Model 2. Model 1 is not compatible with remissions
lasting less than 150 days. For simplicity we count all leukemic cell types as blasts.
5.4 Model with mutations
In the following we describe an extension of Model 1 which includes mutations. There is
an evidence that a preleukemic HSC compartment serves as a reservoir of accumulated
mutations [33]. This hypothesis is supported by the finding that some of the mutations
recurrently observed in leukemia already exist in the HSC compartment of a majority
of leukemia patients [33]. These preleukemic HSC seem to behave similarly to normal
HSC [33]. The hypothesis is that a relatively small number of additional hits may
transform these preleukemic HSC into LSC. Nevertheless details of the underlying
dynamics are not well understood [33].
We make the following assumptions:
• LSC with new properties can be generated either from preleukemic HSC or from
LSC due to acquisition of mutations. This is in line with the current knowledge
[7, 32].
• For simplicity we assume that the influx of new LSC from the preleukemic com-
partment is constant in time. This assumption is made due to simplicity, since
at the moment the dynamics of the preleukemic compartment is not well under-
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stood [33]. We neglect mutations leading from normal HSC, i.e. non-preleukemic
HSC to LSC.
• We assume that most mutations in LSC are acquired during replication of the
genome and neglect other possible origins. In line with [7] we neglect mutations
leading to dedifferentiation of non-LSC leukemic cells.
Let li1(t) be the level of LSC of clone i at time t. The flux to mitosis is then
li1(t)p
li(t). Out of mitosis we obtain 2al
i
(t)pl
i
(t)li1(t), where a
li(t) is the fraction of
LSC self-renewal of clone i at time t. We assume that the fraction ν of these cells is
mutated, ν takes into account replication errors in relevant genes and is assumed to be
constant. The influx αi(t) of mutated LSCs due to new mutations occurring in clone
i at time t is therefore 2al
i
(t)pl
i
(t)li1(t)ν.
We obtain the following set of equations describing dynamics of clone i:
d
dt
li1(t) = 2a
li(t)pl
i
(t)li1(t)(1− ν)− pl
i
(t)li1
d
dt
li2(t) = 2(1− al
i
(t))pl
i
(t)li1(t)− dl
i
2 l
i
2(t)
αi(t) = 2a
li(t)pl
i
(t)li1(t)ν
A similar system of equations has been obtained by Traulsen et al [83]. Since li2
is considered to be postmitotic, we do not distinguish between cells that acquired a
mutation during the divisions and those that did not.
The influx α(t) of mutated cells at time t is given by
α(t) = γ +
∑N(t)
i=1 αi(t), where γ is the constant influx from the preleukemic com-
partment and N(t) the number of leukemic clones present at time t.
We accept the rate α(t) as the rate of an inhomogeneous Poisson process. Poisson
processes describe rare events [84, 85], therefore they are a suitable tool to model
mutations. It is known from probability theory that, if τ1 is a jump time of the
inhomogeneous Poisson with rate λ(t), then the next jump time τ2 can be generated
by solving the equation
∫ τ2
τ1
λ(t)dt = − log(1 − u) for τ2. Here u is an uniformly
distributed random variable u ∈ [0, 1] [86]. We further know that if u is uniformly
distributed in u ∈ [0, 1] then − log(1− u) is exponentially distributed with parameter
1 [85].
We simulate the system with mutations as follows: At time t0 = 0 we draw an
exponentially distributed random number r1 with parameter 1. We simulate the system
until the timepoint t1 which fulfills
∫ t1
t0
λ(t)dt = r1. At timepoint t1 a mutation occurs
that gives rise to a new LSC. This is modelled by adding to the system a new LSC clone,
consisting of one LSC and no less primitive leukemic cells. We assume that the mutation
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occurs in a random gene position therefore we assign random cell properties to the new
clone, i.e. self-renewal and proliferation chosen randomly from uniform distributions
(proliferation rate between 0.01 and 0.9, self-renewal between 0.5 and 1). This choice
is made for the sake of simplicity since details about the impact of mutations on cell
behaviour and the underlying probability distributions are not known [1]. We then
draw another random number r2 and continue simulations until timepoint t2 fulfilling∫ t2
t1
λ(t)dt = r2, etc. We start simulations from the equilibrium of the hematopoietic
system and one LSC with random properties.
The results obtained from these simulations are similar to the results from the
model without mutations. At primary diagnosis cells show high self-renewal and high
proliferation while at relapse cells show high self-renewal and reduced proliferation
(Supplemental Figure 3). The proliferation rates differ significantly between diagno-
sis and relapse (p < 10−6 in Kruskal-Wallis Test), while self-renewal does not differ
significantly (p ≈ 0.7 in Kruskal-Wallis test).
Patient 1 Patient 2
Gender Male Male
Age at diagnosis 63 60
Diagnosis AML AML FAB M2
Therapy Days 30-37 (Induction):
- Mitoxantron(10 mg/m2) (d 1-3)
- AraC (2000 mg/m2) (d 1,3,5,7)
Days 70-74 (Consolidation):
- Mitoxantron(10 mg/m2) (d 1,2)
- AraC (1000 mg/m2) (d 1,3,5)
Days 1-7 (Induction I)
-AraC(100 mg/m2)(d1-7)
-DA(60mg/m2)(d3-5)
Days 23-29 (Induction II)
-AraC(100 mg/m2)(d1-7)
-DA(60mg/m2)(d3-5)
Days 60-64 (Consolidation I)
-AraC(6000 mg/m2)(d1,3,5)
Days 109-113 (Consolidation II)
-AraC(6000 mg/m2)(d1,3,5)
Days 145-146 (Conditioning)
-Allogeneic, HLA-identical HSCT
(after Treosulfan/Fludarabin/ATG)
Table 1: Demographic and treatment data of the 2 patients considered. Day 0 is defined
as the day of diagnosis. ATG=Anti-Thymocyte Globulin, HSCT=Hematopoietic Stem Cell
Transplantation.
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Cell Property Clone 1 Clone 2 Clone 3
Leukemic cell proliferation rate (1/days) 0.25 0.25 1.2
Leukemic cell self-renewal 0.755 0.76 0.6
Blast death rate (1/days) 0.5 0.5 0.5
kchemo (Induction) 3 3 3
kchemo (Consolidation) 3 3 3
Table 2: Parameters used for Patient 1: The parameters of the hematopoietic lineage result
from the model calibration shown in the Supplement. Simulations are based on Model 2. The
function d(x), describing cell death due to space competition has been set to max(0, x− 3c),
where c is steady state bone marrow cell count in absence of leukemic cells.
Cell Property Clone 1 Clone 2
Leukemic cell proliferation rate (1/days) 0.45 1.2
Leukemic cell self-renewal 0.75 0.6
Blast death rate (1/days) 0.5 0.5
kchemo (Induction I, II) 3 3
kchemo (Consolidation I, II) 5 5
kchemo (Conditioning) 16 16
Table 3: Parameters used for Patient 2: The parameters of the hematopoietic lineage are
chosen due to the calibration shown in the Supplement. Simulations are based on Model 2.
The function d(x), describing cell death due to space competition has been set to max(0, x−
3c), where c is steady state bone marrow cell count in absence of leukemic cells.
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Figure 1: Schematic Representation of the Models: In Model 1 (a) self-renewal of leukemic
and hematopoietic cells depends on the total number of postmitotic cells via negative feed-
back. In Model 2 (b) self-renewal of hematopoietic cells depends on mature blood cell counts.
Leukemic cells are independent of hematopoietic feedback signals. Increasing cell numbers
in bone marrow space lead to increasing death rates of all bone marrow cell types, namely
mitotic hematopoietic and all leukemic cells.
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Figure 2: Impact of growth properties on clonal selection. The figures depict clonal selection
in 50 simulated patients. Each black ’.’ marks cellular properties of a leukemic clone present
at the beginning of the simulations in at least one patient. Each ’+’ marks properties of a
leukemic clone contributing significantly to the leukemic cell mass at diagnosis in at least
one patient. Leukemic cells present at diagnosis have high proliferation rates and high self-
renewal potential. (a): Model 1, (b): Model 2.
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Figure 3: Impact of growth properties on clonal selection. The figures depict clonal selection
in 50 simulated patients. Each black ’.’ marks cellular properties of a leukemic clone present
at the beginning of the simulations in at least one patient. Each ’+’ marks properties of a
leukemic clone contributing significantly to the leukemic cell mass at diagnosis in at least one
patient. Gray squares mark properties of cell clones contributing significantly to relapse after
chemotherapy in at least one patient. In comparison to leukemic cells present at diagnosis,
clones at relapse have lower proliferation rates. (a): Model 1, strong chemotherapy, (b):
Model 1, weak chemotherapy, (c): Model 2, strong chemotherapy, (d): Model 2, weak
chemotherapy. (e) Example of the dynamics of hematopoietic (left) and leukemic (right)
cells in one simulated patient. Vertical dotted lines mark primary diagnosis and relapse.
Therapy is indicated by a gray rectangle. In the given example primary manifestation and
relapse of the disease are diagnosed when mature blood cells decreased by 50%.
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Figure 4: Time dynamics and clonal composition of subsequent relapses. The figure depicts
an example of multiple relapses after chemotherapy. Relapses are treated using the same
strategy as primary presentation. (a) Leukemic cell counts, each color indicates a different
clone. Time between relapses 2, 3 and 4 is shorter than remission after first treatment. This
demonstrates that the selected clones are not fully responsive to the applied therapy. (b)
Clonal composition of leukemic cell mass at the primary diagnosis and at relapses. Charts
depict the contribution of major clones to the total leukemic cell mass. Clones responsible
for relapse are present at very small fractions at primary diagnosis (<< 5%). Relapses are
triggered by the same clones but their relative contribution to the leukemic cell mass change
in favour of the slowly proliferating highly self-renewing cells.
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Figure 5: First Phase of Leukemic Clone Evolution: At the beginning fast proliferating
clones with low self-renewal can dominate. They are later out-competed by clones with
high self-renewal, which is an advantage under high competition for niche spaces, needed
for self-renewal. If there exist clones with high self-renewal and high proliferation, they will
dominate during this first phase of leukemic evolution. Each line type corresponds to one
leukemic clone. Blasts are immature cells used for diagnosis of leukemias. In the course of
the disease blasts accumulate and outcompete hematopoiesis. Blast counts greater than 5%
are considered as pathological [70]. The simulations are based on Model 1.
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Figure 6: Fitting of model to patient data. Different leukemic mutations are used to dis-
tinguish between different clones. (a) The table indicates presence and absence of different
leukemic clones at different timepoints of the disease. Arrows indicate if the respective
clones increased or decreased during the time interval between the measurements. The de-
picted data are based on PCR analysis of bone marrow cells. (b) Comparison of simulated
blast counts to data. Data are indicated as squares. (c) Evolution of leukemic populations.
Each clone is indicated by a different line type. (d) Simulated counts of healthy leukocytes.
Chemotherapy cycles are indicated by gray rectangles.
Figure 7: Fitting of model to patient data. Different leukemic mutations are used to dis-
tinguish between different clones. (a) The table indicates presence and absence of different
leukemic clones at different timepoints of the disease. Arrows indicate if the respective clones
increased or decreased during the time interval between the measurements. Small arrows
indicate small changes, large arrows large changes. The depicted data are based on PCR
analysis of bone marrow cells. (b)-(c): Evolution of leukemic populations with differently
scaled vertical axis (cells per kg of body weight). Each clone is indicated by a different line
type. (d): Comparison of simulated blast counts to data. Data are indicated as squares. (e):
Simulated counts of healthy leukocytes in cells per kg of body weight. Chemotherapy cycles
are indicated by gray rectangles. 38
Appendix - Figure 1: Clones contributing to relapse (Model 1). The Figure shows the
distribution of the number of clones that contribute to diagnosis. The number of clones
present at the beginning is 25 (a), 50 (b), 75 (c) or 100 (d). The simulations include 1000
patients. The Figure shows that for all initial conditions (a)-(d) the number of contributing
clones is relatively constant (3 or less for more than 80% of the patients).
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Appendix - Figure 2: Clones contributing to relapse (Model 2). The Figure shows the
distribution of the number of clones that contribute to diagnosis. The number of clones
present at the beginning is 25 (a), 50 (b), 75 (c) or 100 (d). The simulations include 1000
patients. The Figure shows that for all initial conditions (a)-(d) the number of contributing
clones is relatively constant (5 or less for more than 80% of the patients). In Model 2 the
average number of clones contributing to relapse is slightly higher than in Model 1.
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Appendix - Figure 3: Clonal properties at diagnosis and at relapse in a model with muta-
tions. The Figure shows the distribution of self-renewal and proliferation rate of leukemic
clones present at diagnosis and at relapse. The plots include data of 500 simulated patients.
As in the models without mutations, proliferation is reduced at relapse in comparison to
diagnosis while self-renewal is high at both timepoints. (a) proliferation rate at diagnosis,
(b) proliferation rate at relapse, (c) self-renewal at diagnosis, (d) self-renewal at relapse.
The simulations are for γ = 0.02/days and for ν = 5 · 10−8, kchemo = 60. Similar results are
obtained for different values, e.g., if γ and ν are varied by a factor of 10.
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